GlassScriptPhysician profile
Margaret E Burnett
NPI 1679500904
$293,229.59
in general payments reported to CMS, 2019-2025
14 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $48K · 2021: $27K · 2022: $46K · 2023: $32K · 2024: $25K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Food and Beverage: $5,119 · Travel and Lodging: $3,030 · Consulting Fee: $1,337 · Education: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,859.00 |
| Food and Beverage | $5,119.01 |
| Travel and Lodging | $3,029.69 |
| Consulting Fee | $1,337.00 |
| Education | $569.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $132,045.96 | 2019-2025 | Tysabri, Vumerity, Tysabri |
| Emd Serono, INC. | $101,311.99 | 2019-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $28,394.06 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $24,202.25 | 2019-2025 | Kesimpta |
| Genzyme Corporation | $4,683.72 | 2019-2024 | |
| Banner Life Sciences, LLC | $800.00 | 2020 | |
| Horizon Therapeutics Plc | $690.53 | 2021-2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $467.26 | 2023-2025 | Ultomiris, Soliris |
| Amgen INC. | $353.10 | 2024 | Uplizna |
| Janssen Pharmaceuticals, INC | $99.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $59.00 | 2023 | |
| Genentech, INC. | $48.95 | 2023 | Ocrevus |
| Teva Pharmaceuticals USA, INC. | $41.16 | 2019 | |
| Celgene Corporation | $32.61 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Burnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.